Neurocrine Biosciences, Inc.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Neurocrine Biosciences, Inc.'s yearly results (2022–2025), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
What stands out
- Self-Funding Ratio: Over the last 3 years its own operating cash covered its investment spending (capex) 17.6 times. Higher than 97% of Healthcare companies in United States.
- Steadiness Ratio: Sales and profit both grew in each of the last 3 years. Steadier than 96% of Healthcare companies in United States.
Cash quality
Profit Cash Ratio
$165Over the last 3 years, every $100 of reported profit came with $165 of operating cash.
Higher than 61% of Healthcare companies in United States.
Self-Funding Ratio
17.6×Over the last 3 years its own operating cash covered its investment spending (capex) 17.6 times.
Higher than 97% of Healthcare companies in United States.
Cash Locked Ratio
$20For every $100 of sales, $20 is tied up in day-to-day operations (money owed by customers + stock − money owed to suppliers), against $21 tied up three years earlier.
Less money tied up than 56% of Healthcare companies in United States.
Growth quality
Steadiness Ratio
3/3 · 3/3Sales and profit both grew in each of the last 3 years.
Steadier than 96% of Healthcare companies in United States.
Growth Efficiency Ratio
$24Sales grew 92% in 3 years; of every extra $100 of sales, $24 became extra profit.
Higher than 54% of Healthcare companies in United States.
Asset Productivity Ratio
+92% / +96%In 3 years sales changed by +92% while total assets changed by +96%. Both moved at about the same pace.
Balance-sheet strength
Debt Due Cover Ratio
—Data incomplete
Cash Cushion Ratio
+7%Cash, after subtracting all debt, equals 7% of its market value (net cash).
Lower than 53% of Healthcare companies in United States.
Tangible Assets Ratio
—Data incomplete
Tangible Net Worth Ratio
—Data incomplete
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (13)
Neurocrine Biosciences, Inc. owes $0.31 for every $1 it owns. Net profit rose 40% in the year to Dec 2025, and grew 46% a year on average over 3 years.
Compared with Healthcare companies in United States · latest annual results Dec 2025.
P/E ratio
21.0Investors pay $21.0 for every $1 of Neurocrine Biosciences, Inc.'s yearly profit, lower than 62% of Healthcare companies in United States.
P/B ratio
3.94The share price is 3.94 times Neurocrine Biosciences, Inc.'s book value per share, higher than 65% of Healthcare companies in United States.
Market cap
$14.6 BThe total market value of all of Neurocrine Biosciences, Inc.'s shares at today's price (share price × number of shares), larger than 93% of Healthcare companies in United States. PosiCap size class: Tito Cap.
Net worth (book value)
$3.7 BWhat Neurocrine Biosciences, Inc. would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (30 Jun 2026).
Book value per share
$36.34Net worth divided by the number of shares. The share price of $143.29 is 3.9 times this, which is the P/B above.
Return on equity (ROE)
22.1%Neurocrine Biosciences, Inc. earned 22.1% on its shareholders' money over the last year, higher than 91% of Healthcare companies in United States.
Owes vs Owns
0.31×Neurocrine Biosciences, Inc. owes $0.31 for every $1 it owns (low), lower than 59% of Healthcare companies in United States.
Dividend yield
NoneNeurocrine Biosciences, Inc. does not currently pay a dividend.
Revenue growth
+21%Revenue rose 21% in the year to Dec 2025, and grew 24% a year on average over 3 years.
Profit growth
+40%Net profit rose 40% in the year to Dec 2025, and grew 46% a year on average over 3 years.
Profit margin
16.7%Neurocrine Biosciences, Inc. keeps $17 of every $100 of revenue as net profit.
Cash quality
1.6×Cash from Neurocrine Biosciences, Inc.'s business was 1.6× its reported profit in the year to Dec 2025 — its profit turned into cash.
Cash vs debt
Net cashNeurocrine Biosciences, Inc. held $1.1 B more cash than debt (net cash) at Dec 2025.
Questions
What is Neurocrine Biosciences, Inc.'s P/E ratio?
Investors pay $21.0 for every $1 of Neurocrine Biosciences, Inc.'s yearly profit, lower than 62% of Healthcare companies in United States.
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Neurocrine Biosciences, Inc.: $14.6 B ÷ $3.7 B (30 Jun 2026) = 3.9.
What is Neurocrine Biosciences, Inc.'s return on equity?
Neurocrine Biosciences, Inc. earned 22.1% on its shareholders' money over the last year, higher than 91% of Healthcare companies in United States.
How much does Neurocrine Biosciences, Inc. owe compared with what it owns?
Neurocrine Biosciences, Inc. owes $0.31 for every $1 it owns (low), lower than 59% of Healthcare companies in United States.
Does Neurocrine Biosciences, Inc. pay a dividend?
No. Neurocrine Biosciences, Inc. does not currently pay a dividend.
Is Neurocrine Biosciences, Inc.'s revenue growing?
Revenue rose 21% in the year to Dec 2025, and grew 24% a year on average over 3 years.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.